Allarity Therapeutics Funding Round

3/6/2026

Debt

$20,000,000

Undisclosed

The Company intends to use the proceeds primarily to support key initiatives designed to accelerate the advance of stenoparib toward pivotal development, FDA approval and commercialization.

Private & Independent

Biopharmaceutical

123 E Tarpon Ave
Tarpon Springs, FL 34689
USA

Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing stenoparib for the treatment of advanced, recurrent ovarian cancer. At Allarity we leverage our proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Our DRP® technology has been broadly validated across an extensive array of therapies and tumor types with a high degree of accuracy for matching the right patient to the right drug. By identifying those patients who will and who will not respond, the DRP® companion diagnostics have the potential to transform cancer therapeutic development across many indications by increasing clinical success rates with trials involving a fewer number of patients, and improve patient outcomes by matching them to the right drug. Publicly traded on NASDAQ, Allarity Therapeutics (ALLR). Allarity Therapeutics (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersho